US 11,590,136 · Application 17/704,180 · Granted Feb 28, 2023
US 11,590,136
Topical formulation for a jak inhibitor
Estimated expiration
May 20, 2031
4y 233d remaining
Earliest effective filing
May 20, 2011
+ 20 years
May 20, 2031
PTA +0d
May 20, 2031
TD cap (US 11,219,624)
May 20, 2031
Final
May 20, 2031
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- March 25, 2022
- Earliest effective filing
- May 20, 2011
- Issue date
- February 28, 2023
- PTA
- 0 days
- Base expiry (before PTA)
- May 20, 2031
May 20, 2011 + 20 years = May 20, 2031
- Continuation of application 17/541,439, filed Dec 3, 2021, issued as US 12,622,908
- Continuation of application 16/948,408, filed Sep 17, 2020, issued as US 11,219,624
- Continuation of application 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
- Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
- Continuation of application 14/714,820, filed May 18, 2015
- Continuation of application 13/112,370, filed May 20, 2011
- Continuation of application 13/112,370, filed May 20, 2011
- Continuation of application 14/714,820, filed May 18, 2015
- Continuation of application 13/112,370, filed May 20, 2011
- Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
- Continuation of application 14/714,820, filed May 18, 2015
- Continuation of application 13/112,370, filed May 20, 2011
- Continuation of application 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
- Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
- Continuation of application 14/714,820, filed May 18, 2015
- Continuation of application 13/112,370, filed May 20, 2011
- Continuation of application 16/948,408, filed Sep 17, 2020, issued as US 11,219,624
- Continuation of application 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
- Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
- Continuation of application 14/714,820, filed May 18, 2015
- Continuation of application 13/112,370, filed May 20, 2011
- PRO61/347,132 — Provisional — not used for base term
- PRO61/347,132 — Provisional — not used for base term
- PRO61/347,132 — Provisional — not used for base term
- PRO61/347,132 — Provisional — not used for base term
- PRO61/347,132 — Provisional — not used for base term
- PRO61/347,132 — Provisional — not used for base term
- PRO61/347,132 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to May 20, 2031 (earliest expiring referenced patent: US 11,219,624)
US 12,092,001· Application 18/355,334Capping patent
Method for controlling an internal combustion engine including at least one exhaust-gas aftertreatment component having an electric heating element
- Filing date
- Jul 19, 2023
- Earliest effective filing
- Jul 19, 2023
- Issue date
- Sep 17, 2024
- PTA
- 0 days
- Calculated expiration
- Jul 19, 2043
Jul 19, 2023 + 20y = Jul 19, 2043
US 11,219,624· Application 16/948,408Capping patent
Topical formulation for a jak inhibitor
- Filing date
- Sep 17, 2020
- Earliest effective filing
- May 20, 2011
- Issue date
- Jan 11, 2022
- PTA
- 0 days
- Calculated expiration
- May 20, 2031
Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Continuation of 13/112,370, filed May 20, 2011
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
May 20, 2011 + 20y = May 20, 2031
US 10,869,870· Application 16/947,735
Topical formulation for a jak inhibitor
- Filing date
- Aug 14, 2020
- Earliest effective filing
- May 20, 2011
- Issue date
- Dec 22, 2020
- PTA
- 0 days
- Calculated expiration
- May 20, 2031
Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Continuation of 13/112,370, filed May 20, 2011
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
May 20, 2011 + 20y = May 20, 2031
US 10,758,543· Application 16/566,625
Topical formulation for a jak inhibitor
- Filing date
- Sep 10, 2019
- Earliest effective filing
- May 20, 2011
- Issue date
- Sep 1, 2020
- PTA
- 0 days
- Calculated expiration
- May 20, 2031
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Continuation of 13/112,370, filed May 20, 2011
May 20, 2011 + 20y = May 20, 2031
US 11,590,136· Application 17/704,180(from application 17/704,180)
Topical formulation for a jak inhibitor
- Filing date
- Mar 25, 2022
- Earliest effective filing
- May 20, 2011
- Issue date
- Feb 28, 2023
- PTA
- 0 days
- Calculated expiration
- May 20, 2031
Continuation of 17/541,439, filed Dec 3, 2021, issued as US 12,622,908
Continuation of 16/948,408, filed Sep 17, 2020, issued as US 11,219,624
Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Continuation of 13/112,370, filed May 20, 2011
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
Continuation of 16/948,408, filed Sep 17, 2020, issued as US 11,219,624
Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
Continuation of 14/714,820, filed May 18, 2015
Continuation of 13/112,370, filed May 20, 2011
May 20, 2011 + 20y = May 20, 2031
Notes (1)
- [TD_REFS_TRUNCATED] Found 8 TD references; resolving first 5 only
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/704,180 · US 11,590,136
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,590,136: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11590136Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.